The pharmaceutical sector continues to experience robust growth, driven by a surge in innovative research, the advent of advanced technologies, and an increasing global demand for effective healthcare solutions. This

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development,

Poolbeg Pharma, founded by Cathal Friel, operates with a distinct approach to funding and development. Friel, a renowned financier, has a track record of successfully launching and selling companies through

Pharmaceutical giants like Merck KGaA are increasingly partnering with AI companies, signaling a trend in the drug development landscape where emerging technologies are adopted to expedite and improve the drug

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of

The year 2020 will be remembered for its tragic events, but in its wake, companies like Poolbeg Pharma are leading efforts to prepare for future pandemics. Richard Staines from Optimum

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost